share_log

Aptevo Therapeutics Shares Drop 28% After More Than Doubling Tuesday

Dow Jones Newswires ·  Nov 24, 2021 10:30

By Chris Wack

Aptevo Therapeutics Inc. shares were down 28% to $12.31 Wednesday, one day after rallying following news from the company that a patient in a Phase 1b study of its lead proprietary drug candidate APVO436 in acute myeloid leukemia had a complete remission.

Volume for the stock was 5.2 million shares at 10:15 a.m. ET, compared with a 65-day average volume of 2.6 million. The stock hit its 52-week low of $6.38 on Monday and closed Tuesday's session up 163%.

The company said one high-risk patient achieved a complete remission after one cycle of therapy, without evidence of overt toxicity.

Aptevo said the goal of the multi-center, multi-cohort study is to determine if APVO436 treatments can improve the quality of remission in high-risk patients by reducing the residual chemotherapy-resistant measurable residual disease burden.

Write to Chris Wack at chris.wack@wsj.com

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment